The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
Company Announcement COPENHAGEN, Denmark; February 12, 2025 - Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback